Key result
Recent advances in Von Willebrand disease management include improved bleeding assessment tools, new laboratory assays such as VWF:GPIbM, and treatment options like recombinant VWF.
This review summarizes recent diagnostic and therapeutic advances in Von Willebrand disease, emphasizing the need for continued improvement in patient management and quality of life.
Answers are grounded in this paper and cite their sources.
May refine VWD diagnosis and therapy; leaves open prospective validation of new tools and recombinant VWF.
Von Willebrand disease (VWD) is the most common inherited bleeding disorder, yet diagnosis and management remain challenging. Development and use of bleeding assessment tools allows for improved stratification of which patients may require further assessment and which patients are most likely to require treatment of their VWD. New options for laboratory assessment of von Willebrand factor (VWF) activity include a new platelet-binding assay, the VWF:GPIbM, which is subject to less variability than the ristocetin cofactor activity assay, and collagen-binding assays that provide insight into a different function of VWF. Genetic testing may be helpful in some cases where a type 2 VWD variant is suspected but is usually not helpful in type 1 VWD. Finally, treatment options for VWD are reviewed, including the use of recombinant VWF. Despite these advances, still more work is required to improve diagnosis, treatment, and quality of life for affected patients.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2017) conducted a review in Von Willebrand disease. Advances in diagnosis and treatment was evaluated. Recent advances in Von Willebrand disease management include improved bleeding assessment tools, new laboratory assays such as VWF:GPIbM, and treatment options like recombinant VWF.
Synapse has enriched 10 related papers. Consider them for comparative context: